All In Biotech

Drug Trial Radar · NCT05277168

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

May 30, 2022

Primary completion

May 2026

Study completion May 2026

Sponsor

Sponsor type
Industry
First posted
Mar 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SHR-A1904Drug

    Single Arm :It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: The first cycle of administration, up to 21 days.
  2. Maximum tolerated dose (MTD)Time frame: The first cycle of administration, up to 21 days.
  3. Recommended Phase 2 Dose (RP2D)Time frame: The first cycle of administration, up to 21 days.
  4. Adverse events (AEs) and serious adverse events (SAEs)Time frame: From the signing of informed consent form to the end of safety follow-up period (90 days after the last dose).

Locations

28 sites in 4 countries. Site status is shown where the registry gives one.

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida · Active not recruiting

  • Comprehensive Hematology Oncology

    St. Petersburg, Florida · Terminated

  • LSU Health Sciences Center

    New Orleans, Louisiana · Active not recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Terminated

  • Rhode Island Hospital

    Providence, Rhode Island · Terminated

  • Prisma Health

    Greenville, South Carolina · Active not recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • Central Coast Local Health District

    Gosford, New South Wales, Australia · Completed

  • Sydney South West Private Hospital

    Liverpool, New South Wales, Australia · Completed

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia · Completed

  • Genesis Care North Shore

    St Leonards, New South Wales, Australia · Completed

  • Macquarie University

    Sydney, New South Wales, Australia · Completed

  • Westmead Hospital

    Westmead, New South Wales, Australia · Completed

  • Gold Coast Private Hospital

    Southport, Queensland, Australia · Completed

  • Peninsula and South Eastern Haematology & Oncology Group (PASO)

    Frankston, Victoria, Australia · Completed

  • One Clinical Research (OCR)

    Nedlands, Western Australia, Australia · Completed

  • National Institute of Oncology, Arensia Research Clinic

    Chisinau, Moldova · Active not recruiting

  • Dong-A University Hospital

    Busan, South Korea · Recruiting

  • Chungbuk National University Hospital

    Cheongju-si, South Korea · Recruiting

  • Ajou University Hospital

    Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam, South Korea · Recruiting

  • CHA Bundang Medical Centre

    Seongnam-si, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.